<DOC>
	<DOCNO>NCT01072695</DOCNO>
	<brief_summary>This phase 2 , randomize , open-label trial GS-9256 plus GS-9190 , two oral anti HCV drug , 28 day without ribavirin ( RIBA ) pegylated interferon ( PEG ) /RIBA adult chronic Hepatitis C virus ( HCV ) . In Part A , approximately thirty ( 30 ) subject 18-70 year age meet study entry criterion randomize ( word , select random , like flip coin ) one two treatment group ( GS-9256 plus GS-9190 GS-9256 plus GS-9190 plus RIBA ) . In Part B , additional fifteen ( 15 ) subject receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID combination PEG/RIBA . After 28-day treatment period , subject receive PEG/RIBA standard care ( SOC ) . Following randomization , subject return Baseline ( Day 1 ) visit , time study medication dispense subject enter 28 day treatment phase . During treatment phase , subject receive oral study drug twice daily 28 day PEG weekly Part B . Subjects receive PEG/RIBA local SOC start Day 28 ( provide part study ) . Following completion 28-day treatment phase , subject follow approximately 72 week .</brief_summary>
	<brief_title>Efficacy Safety Study GS-9256 GS-9190 Alone Combination With Ribavirin 28 Days Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>GS-9256 ( HCV NS3 protease inhibitor ) plus GS-9190 ( non-nucleoside HCV NS5B inhibitor ) administer 28 day without RIBA ( weight-based dosing ) PEG/RIBA treatment-naïve subject chronic genotype 1 HCV infection . In Part A , thirty ( 30 ) subject genotype 1 randomize 75 mg GS-9256 BID plus 40 mg GS-9190 BID 75 mg GS-9256 BID plus 40 mg GS-9190 BID plus RIBA 1000-1200 mg/day 28 day . In Part B , additional fifteen ( 15 ) subject genotype 1 receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID combination PEG/RIBA 28 day . After 28-day treatment period , subject receive PEG/RIBA standard care ( SOC ) . In Part A , subject meet pre-defined , individual , virologic criterion , PEG/RIBA standard care start prior Day 28 . Both PEG RIBA administer currently approve dosage treatment HCV infection accordance appropriate labeling . Subjects monitor safety ( include ECG monitoring ) , antiviral activity , pharmacokinetics , resistance 2-3 time weekly Day 28 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult subject , age 1870 Willing able provide inform consent BMI 18 36 kg/m2 ( inclusive ) Chronic HCV infection , genotype 1 HCV RNA &gt; /= 3 log , &lt; 7.2 log10 IU/ml screen Liver biopsy , FibroTest , FibroScan indicate absence cirrhosis HCV treatment naïve imminent plan start treatment PEG/RIBA QTcF &lt; /= 450 msec screen ALT , AST , GGT &lt; 5 X ULN screen visit Creatinine clearance &gt; = 50 mL/min Absolute neutrophil count &gt; = 1500/mm3 Hemoglobin &gt; /= 12 g/dL ( female ) , &gt; /= 13 g/dL ( male ) Males agree use effective contraception refrain sperm donation Able comply dose instruction study visit Of generally good health Females childbearing potential male female partner pregnant plan become pregnant Infection HCV genotype multiple HCV genotypes Poorly control diabetes Hemoglobinopathy know retinal disease History sarcoidosis invasive malignancy Untreated significant psychiatric illness Coinfection hepatitis B virus human immunodeficiency virus Chronic use systemic immunosuppressive agent Autoimmune disorder Severe COPD History significant cardiac disease Known cirrhosis NonHCV chronic liver disease Transplantation Suspicion hepatocellular carcinoma Bilirubin normal range Gilbert 's syndrome Decompensated liver disease Clinically significant illness GI disease could interfere absorption Acute porphyria Current excessive alcohol ingestion , average &gt; 3 drinks/day female &gt; 4 drinks/day male current binge drinking Positive urine drug screen History difficult blood collection Significant recent blood loss Prohibited medication , include H2 antagonist , investigational agent Restricted fruit , fruit juice Hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>GS-9256</keyword>
	<keyword>GS-9190</keyword>
	<keyword>Genotype 1</keyword>
</DOC>